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Abstract
Introduction—For many men, the net benefit of prostate cancer screening with prostate-specific 
antigen (PSA) tests may be small. Many major medical organizations have issued 
recommendations for prostate cancer screening, stressing the need for shared decision making 
before ordering a test. The purpose of this study is to better understand associations between 
discussions about benefits and harms of PSA testing and uptake of the test among men aged ≥40 
years.
Methods—Associations between pre-screening discussions and PSA testing were examined 
using self-reported data from the 2012 Behavioral Risk Factor Surveillance System. Unadjusted 
prevalence of PSA testing was estimated and AORs were calculated using logistic regression in 
2014.
Results—The multivariate analysis showed that men who had ever discussed advantages of PSA 
testing only or discussed both advantages and disadvantages were more likely, respectively, to 
report having had a test within the past year than men who had no discussions (p<0.001). In 
addition, men who had only discussed the disadvantages of PSA testing with their healthcare 
providers were more likely (AOR=2.75, 95% CI=2.00, 3.79) to report getting tested than men who 
had no discussions.
Conclusions—Discussions of the benefits or harms of PSA testing are positively associated 
with increased uptake of the test. Given the conflicting recommendations for prostate cancer 
screening and increasing importance of shared decision making, this study points to the need for 
understanding how pre-screening discussions are being conducted in clinical practice and the role 
played by patients’ values and preferences in decisions about PSA testing.
Introduction
For many men, the benefits of prostate cancer screening with prostate-specific antigen 
(PSA) tests may be small compared with the potential for harms related to overdiagnosis and 
overtreatment.1,2 In 2012, the U.S. Preventive Services Task Force (USPSTF) expanded its 
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2008 recommendation against PSA-based screening for prostate cancer among men aged 
≥75 years to also include men of all ages.2,3 In 2013, the American Urological Association 
and the American College of Physicians updated their recommendations, narrowing the 
screening age to 55–69 years and 50–69 years, respectively, and strongly emphasized the 
requirement of shared decision making (SDM) before ordering the test.4,5
Owing to the uncertainty of PSA testing in mortality reduction and the potential harms, most 
prostate cancer screening guidelines recommend that, before testing, clinicians should have 
a balanced discussion with patients about the advantages and disadvantages of the test and 
its scientific uncertainties of effectiveness in reducing mortality.4–6 The process in which 
both the patient and clinician share information with each other and take steps to make a 
decision is commonly referred to as SDM.4–6
In 2012, the USPSTF revised the grade assigned to PSA-based testing from the previous “I” 
(insufficient evidence) to a “D” grade, indicating that physicians are under no obligation to 
initiate discussions with patients about PSA testing services.2,7 However, the USPSTF 
understands that screening decisions may differ based on specific patient characteristics and 
clinical situations, and that patients who clearly express an interest in PSA testing should 
make informed decisions about whether testing is right for them.2
The role of key SDM elements in influencing PSA testing has not been well studied.8 In this 
study, associations between patient reports of discussions about benefits and harms of PSA 
testing and uptake of the PSA test are examined.
Methods
This study used data from the 2012 Behavioral Risk Factor Surveillance System (BRFSS), a 
state-based telephone survey of health risk behaviors, preventive health practices, and 
healthcare access among the non-institutionalized U.S. civilian population aged ≥18 years in 
the 50 states and the District of Colombia (www.cdc.gov/BRFSS/). The median response 
rate of the 2012 BRFSS was 49.7%.9
The primary outcome of this analysis was defined as receipt of a PSA test, which was a part 
of a routine exam within the 12 months preceding the survey, among men aged ≥40 years 
who had no history of prostate cancer (Appendix 1, questions A–B). Associations between 
receipt of a PSA test within the past year and discussions of benefits and harms of PSA 
testing were evaluated based on questions about whether men ever had discussions with 
their physicians about the advantages and disadvantages of PSA testing (Appendix 1, 
questions C–D). These two questions were combined to form a new four-category variable: 
ever discussed advantages only, ever discussed disadvantages only, ever discussed both 
advantages and disadvantages, or no discussion.
The analysis was performed in 2014 using SAS-callable SUDAAN, version 9.2 to account 
for the multistage and disproportionate stratified sampling design. Weighted prevalence of 
PSA testing with 95% CIs was estimated and stratified by demographic and health-related 
characteristics. AORs with 95% CIs for having PSA testing were calculated using logistic 
regression analysis while controlling for demographic and health-related characteristics.
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Both bivariate and multivariate analyses showed that the following factors were associated 
with increased receipt of PSA testing in the past year: older age, being non-Hispanic white 
or black, having higher education, being married or living with a partner, being retired, self-
reported excellent/very good health, having a comorbidity, having health insurance, and not 
having medical cost concern (Table 1). After adjusting for the aforementioned variables, 
men who ever discussed advantages of PSA testing alone or discussed both advantages and 
disadvantages were more likely, respectively, to report having a test than men who had no 
discussion (both p-values <0.001). In addition, men who had only discussed the 
disadvantages of PSA testing with their healthcare providers were more likely (AOR=2.75, 
95% CI=2.00, 3.79) to report getting tested than men with no discussions.
Discussion
Similar to the findings of a 2010 National Health Interview Survey (NHIS) study,8 this 
study shows that discussions of advantages of PSA testing alone or discussions of both 
advantages and disadvantages of PSA testing are associated with a higher prevalence of 
receipt of PSA testing. Generally, physician recommendation has been shown to be strongly 
associated with the decision to have a PSA test.10,11 Potential explanations for the 
association between ever discussing both advantages and disadvantages and higher uptake of 
the test might be that: (1) the physician emphasized benefits more frequently than harms or 
gave greater weight to benefits; (2) the physician and patient had a balanced SDM 
discussion, but the patient preferred to undergo PSA testing; or (3) patients had already 
made up their minds to have a test before the discussion. This study appears to be the first to 
identify a positive association between discussions of disadvantages only and PSA testing. 
This finding suggests that patients undertook PSA testing despite physicians’ 
discouragement. Studies have shown that the prevalence of PSA testing among men aged 
≥75 years remains high even after release of the 2008 USPSTF prostate cancer 
recommendations.8,12 Moreover, Squiers et al.13 surveyed men’s responses to the 2012 
USPSTF recommendations against screening and found that although 33% were undecided, 
54% of the respondents still intended to get a PSA test in the future. It is likely that men who 
have a family history of prostate cancer may ask for PSA testing regardless of how SDM is 
performed. Additional research is warranted to determine the role played by patients’ values 
and preferences in decisions about PSA testing.
The major strength of this study is the use of a large population-based sample, which 
enabled the authors to provide stable prevalence estimates of PSA testing by pre-screening 
discussion strata. However, this study is subject to several limitations. First, the BRFSS data 
were self-reported and thus subject to error. Second, lower response rates increase the 
potential for selection bias; however, these findings are consistent with a prior study using 
NHIS data, which has a higher response rate (60.8%).8 Third, responses to pre-screening 
discussion questions were structured as yes/no, and specific content of the discussions and 
whether these discussions were balanced are not known. Fourth, effects of scientific 
uncertainties of PSA-based screening and patients’ knowledge, values, and preferences on 
PSA testing could not be assessed because this information was not collected in the survey. 
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Fifth, PSA testing may be under-reported in the survey because the test may have been 
conducted without the physician telling the patient.14 Last, respondents might comprehend 
survey questions about physician’s discussion differently15; thus, measurement errors could 
not be ruled out.
Conclusions
Men who have ever discussed the benefits or harms of PSA testing with their healthcare 
providers are more likely to report having received a PSA test in the past year. Given the 
conflicting recommendations of prostate cancer screening and increasing importance of 
SDM, additional research is needed on how pre-screening discussions are being conducted 
in clinical practice and the role played by patients’ values and preferences in decisions about 
PSA testing.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Appendix: Supplementary data
Supplementary data associated with this article can be found at http://dx.doi.org/10.1016/
j.amepre.2015.02.007.
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